1. Doppler ultrasound impacts response to intravenous tocilizumab in rheumatoid arthritis patients
- Author
-
Tanaz A. Kermani, William J. Martin, Veena K. Ranganath, Mihaela Taylor, Nicolette T. Morris, Ami Ben-Artzi, Lynette Avedikian-Tatosyan, George Karpouzas, Geraldine Navarro, Jenny Brook, Gurjit S. Kaeley, Himakar Nagam, Soo Choi, and David Elashoff
- Subjects
musculoskeletal diseases ,medicine.medical_specialty ,medicine.diagnostic_test ,business.industry ,General Medicine ,Logistic regression ,Clinical disease ,medicine.disease ,Gastroenterology ,Rheumatology ,chemistry.chemical_compound ,Tocilizumab ,chemistry ,Erythrocyte sedimentation rate ,Internal medicine ,Rheumatoid arthritis ,medicine ,Doppler ultrasound ,Ultrasonography ,skin and connective tissue diseases ,business - Abstract
Within rheumatoid arthritis (RA) patients treated with intravenous tocilizumab (IV-TCZ), it is unclear if power Doppler ultrasonography (PDUS) can predict future clinical response. This study sought to determine if baseline PDUS or its early changes can predict 12-week and 24-week disease activity outcomes, and quantify the need for dose escalation (4 to 8 mg/kg). Fifty-four RA patients starting IV-TCZ were evaluated at baseline, 4, 6, 12, 16, and 24 weeks using 34-joint PDUS (US34-PDUS), clinical disease activity index (CDAI), 28-joint disease activity score using erythrocyte sedimentation rate (DAS28-ESR), ACR 20/50/70, health assessment questionnaire-disability index (HAQ-DI), and PDUS 20/50/70, a novel measure. Logistic regression models evaluated the predictive utility of US34-PDUS of DAS28-ESR response after adjusting for covariates. Ninety-four percent of patients required dose escalation to 8 mg/kg. US34-PDUS, CDAI, and DAS28-ESR improved significantly over 24 weeks (p
- Published
- 2021